Abenex Acquires Cisbio Bioassays from Argos Soditic

argenx to Acquire Forte Biosciences, Inc.

July 27, 2026

Healthcare Services

argenx entered into a definitive agreement to acquire Forte Biosciences, Inc. for $77 per share in cash, valuing the deal at approximately $2.2 billion. The transaction will be implemented via a tender offer followed by a merger, and is expected to close in Q3 2026 subject to customary closing conditions.

Solabia Acquires Mibelle Biochemistry, Seqens' Botanical Actives and IVD Activity, and Xebios Group

March 5, 2026

Biotechnology

Solabia, a Paris-headquartered biotech platform focused on natural active ingredients and diagnostics solutions, has agreed to acquire three complementary businesses as part of its international expansion strategy. The acquisitions include Switzerland-based Mibelle Biochemistry, France-based Seqens' Botanical Actives and In-Vitro Diagnostics activity, and Germany/Netherlands-based Xebios Group.

Abenex Invests in Santis LAB

September 23, 2024

Food & Beverage

Abenex has completed a minority growth investment in Santis LAB, a Franco‑Swiss laboratory that develops and markets food supplements sold through a network of roughly 2,000 pharmacies. The founders and management will remain operational and are investing alongside Abenex to support Santis' expansion into adjacent markets and new geographies.

BBI Solutions Acquires IBEX Technologies Inc.

April 8, 2024

Biotechnology

BBI Solutions OEM Limited has acquired IBEX Technologies Inc., a Montreal-based developer and manufacturer of high-precision enzymes and diagnostic solutions, with the transaction closing on April 8, 2024. The acquisition expands BBI's recombinant protein and enzyme capabilities to better serve in-vitro diagnostics (IVD) manufacturers and brings IBEX's staff and contract-manufacturing capabilities into BBI's global operations.

Cinven Acquires Majority Stake in BioAgilytix; Cobepa Reinvests

December 20, 2021

Healthcare Services

International private equity firm Cinven has agreed to acquire a majority stake in BioAgilytix through a recapitalization, with current investor Cobepa remaining a significant minority investor. GHO Capital has realised its investment and will exit; the transaction will provide funding to support BioAgilytix’s international expansion, capacity and capability investments, and buy-and-build strategy in large-molecule bioanalytical services. BioAgilytix is headquartered in Durham, North Carolina and employs about 870 staff across the United States, Europe and Australia.

PerkinElmer Acquires Cisbio Bioassays from Abénex

April 26, 2019

Biotechnology

PerkinElmer has acquired Cisbio Bioassays from Abénex (with Cisbio management supporting the sale). Cisbio, headquartered in Codolet, France, is a manufacturer of HTRF assay kits, reagents and custom assay services with more than 200 employees; the acquisition expands PerkinElmer's life‑sciences reagent and screening technology portfolio.